source
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6BGSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.STAT · 1mo ago↗ source
- GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6BGSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines that are due for FDA approval decisions later this year. The UK drugmak…Endpoints · 1mo ago↗ source
- Alcohol study discarded by Trump officials is published in scientific journalA government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.